AQR Capital Management and
APG Asset Management have decreased their stakes in West Pharmaceutical Services. On the contrary,
Bright Rock Capital Management, The Manufacturers Life Insurance Company, and
Magnetar Financial have boosted their holdings. Q2 2024 earnings for West missed estimates despite a boost from strong demand for injectables. Despite underperformance on a daily basis, West's stock has managed to outperform its competition. The company has also slashed its full-year sales forecasts and 2024 profit due to subdued demand. Corporate actions include the unveiling of financial results, a declaration of 3rd Quarter 2024 dividends, and participation in an investor conference. Initiations by
Susquehanna Fundamental Investments and
Fred Alger Management indicate a lower positioning of West Pharmaceutical's stock in their portfolio. However, West Pharmaceuticals maintained a high valuation post Q2 results; the company received FDA clearance for its
Vial2Bag Advanced® 13mm Admixture Device, increased its equity stake in
Daikyo Seiko, Ltd, and announced a landmark collaboration with
Corning.
West Pharmaceutical Services WST News Analytics from Fri, 15 Jul 2016 08:25:28 GMT to Sat, 05 Oct 2024 09:54:35 GMT -
Rating 6
- Innovation 5
- Information 9
- Rumor 4
